Core Viewpoint - Hualan Co., Ltd. is expanding its presence in the "AI + Medicine" sector through the establishment of a joint venture focused on drug repurposing and pharmacovigilance services, despite facing internal dissent from two board members regarding the feasibility of this strategic move [1][4][11]. Group 1: Company Initiatives - Hualan Co., Ltd. has established a subsidiary, Hainan Lingqing Smart Pharmaceutical Technology Co., Ltd., to explore AI applications in the pharmaceutical industry [1][5]. - The company plans to collaborate with a technical team led by former CTO of Insilico LLC, Yu Kaixian, and Academician Liu Jun to set up a joint venture that will leverage knowledge graphs for drug-related services [1][4]. - The joint venture aims to provide intelligent solutions for drug development and safety management by integrating heterogeneous data sources [4][6]. Group 2: Investment and Financial Moves - Hualan Co., Ltd. has made significant investments in AI pharmaceutical companies, including a recent capital increase of 45 million yuan to Hainan Lingqing Smart, raising its registered capital to 500 million yuan [8][9]. - The company has also invested 20 million yuan in Kema Biotechnology to acquire a 9.53% stake, which includes a board seat and priority acquisition rights [7]. Group 3: Board Concerns - Two board members, Cui Ke and Yao Mingfang, have expressed concerns about the feasibility of the AI pharmaceutical initiatives, suggesting that the company should conduct thorough evaluations before proceeding [11][12]. - The board members have highlighted the high technical barriers and the need for stable resources and talent in AI pharmaceutical research, indicating potential operational pressures [6][12]. Group 4: Market Performance - Hualan Co., Ltd. has seen a significant increase in its stock price, with a cumulative rise of 68.9% from January 5 to February 10, outperforming the broader market [13]. - The company’s stock reached a historical high on February 9, signaling strong market expectations for its future performance [13][14].

Core Viewpoint - Hualan Co., Ltd. is actively increasing its investment in the AI pharmaceutical sector by injecting 450 million yuan into its wholly-owned subsidiary, Hainan Lingqing Intelligent Pharmaceutical Technology Co., Ltd., raising its registered capital from 50 million yuan to 500 million yuan, indicating a strong commitment to AI-driven drug development [1][2] Group 1: Investment and Strategic Intent - The capital increase aims to enhance the financial strength of Lingqing Intelligent, which is crucial for its business development and talent acquisition during a key phase of its operational setup [1][2] - This move is part of Hualan's broader strategy to solidify its position in the rapidly evolving AI pharmaceutical industry, which requires significant capital and resource integration capabilities [1][2] Group 2: Market Trends and Industry Context - The AI pharmaceutical market is projected to grow from 11.9 billion USD in 2023 to 74.6 billion USD by 2032, with a compound annual growth rate of 22.6%, highlighting the industry's potential for disruption and innovation [3] - Recent collaborations, such as NVIDIA's partnership with Eli Lilly to invest 1 billion USD in an AI innovation lab, underscore the increasing focus on AI solutions to address long-standing challenges in the pharmaceutical sector [2][3] Group 3: Company Developments and Future Outlook - Hualan has established Lingqing Intelligent as a strategic platform for AI pharmaceutical initiatives, with previous investments and the formation of an expert committee to guide its efforts [3] - The company's ongoing commitment to AI in drug development positions it favorably to capitalize on emerging opportunities in the industry, potentially creating long-term value for shareholders [3]